Molecular profiling of the Basal-like intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer
ERpHER2n-Basal breast cancer represents a clinically high-risk subgroup whose molecular resemblance to TNBC highlights potential therapeutic opportunities, particularly for immunotherapy and DNA repair-targeting treatments.
Authors
- Daniella Black
- Deborah F. Nacer (ORCID: https://orcid.org/0000-0002-7117-1371)
- Mattias Aine (ORCID: https://orcid.org/0000-0002-0851-5952)
- L. Hohmann (ORCID: https://orcid.org/0000-0002-0281-7140)
- Åke Borg (ORCID: https://orcid.org/0000-0002-5793-132X)
- Johan Vallon‐Christersson (ORCID: https://orcid.org/0000-0002-2195-0385)
- Ramsay Bowden (ORCID: https://orcid.org/0000-0003-1138-4452)
- Johan Staaf (ORCID: https://orcid.org/0000-0001-5254-5115)
- Yasin Memari (ORCID: https://orcid.org/0000-0002-1747-542X)
- Serena Nik‐Zainal (ORCID: https://orcid.org/0000-0001-5054-1727)
- Helen Davies (ORCID: https://orcid.org/0000-0001-6381-3664)
Institutions
- Lund University (SE)
- University of Cambridge (GB)
- Cancer Research UK Cambridge Center (GB)
Publication Details
- Journal
- Genome Medicine
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1186/s13073-025-01576-9
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00